{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06270043",
            "orgStudyIdInfo": {
                "id": "809622"
            },
            "organization": {
                "fullName": "University of California, San Diego",
                "class": "OTHER"
            },
            "briefTitle": "Focal Therapy for Localized Prostate Cancer",
            "officialTitle": "A Prospective Registry and Longitudinal Study of Patients Undergoing Focal Therapy for Localized Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "focal-therapy-for-localized-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2034-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2034-02-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-11",
            "studyFirstSubmitQcDate": "2024-02-19",
            "studyFirstPostDateStruct": {
                "date": "2024-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Juan Javier-DesLoges",
                "investigatorTitle": "Assistant Professor of Urology",
                "investigatorAffiliation": "University of California, San Diego"
            },
            "leadSponsor": {
                "name": "University of California, San Diego",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.",
            "detailedDescription": "This observational study will serve to collect data from medical record and review questionnaires before and after focal ablation of prostate tissue. All enrolled subjects will have already undergone or scheduled to receive the focal therapy as part of their prostate cancer treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ],
            "keywords": [
                "Focal Therapy",
                "High Intensity Frequency Ultrasound",
                "Transurethral Ultrasound Ablation",
                "Cryoablation",
                "Irreversible Electroporation"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "10 Years",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Urine and Blood samples will be collected on patients for bio banking and future analysis."
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Focal Therapy",
                    "description": "Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received focal therapy as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study.",
                    "interventionNames": [
                        "Procedure: Focal Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Focal Therapy",
                    "description": "Focal ablation of prostate cancer using different modalities. These modalities include:\n\n* Cryoablation or Cryotherapy\n* Irreversible Electroporation - Nanoknife\n* High Intensity Frequency Ultrasound - FocalOne\n* Transurethral Ultrasound Ablation - TULSA - PRO",
                    "armGroupLabels": [
                        "Focal Therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Oncological Response",
                    "description": "The following definitions will be used for evaluation of oncological response:\n\nComplete response: Ablation of prostate tissue in targeted biopsy cores at 12 months.\n\nIncomplete response: Residual disease at 12 months compared to baseline in target biopsy cores or systematic biopsy cores.",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Erectile Dysfunction",
                    "description": "Assess impact on erections after ablation. The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) questionnaire will be used to evaluate sexual health quality-of-life symptoms for participants pre- and post-ablation.\n\nPatients will receive a score between 0 and 12, 0 being low with a better outcome and 12 being high with a worse outcome.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incontinence",
                    "description": "Assess impact on continence after ablation. The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) questionnaire will be used to evaluate urinary health quality-of-life symptoms for participants pre- and post-ablation.\n\nPatients will receive a score between 0 and 12, 0 being low with a better outcome and 12 being high with a worse outcome.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Prostate cancer recurrence. Patients will be monitored with a Prostate Specific Antigen (PSA) every 6 months until 10 years from the intervention. Patients with a rising PSA will receive a prostate biopsy to determine if they have a recurrence.",
                    "description": "Assess long-term recurrence risk after ablation",
                    "timeFrame": "10 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject has elected or already undergone focal therapy as their standard of care treatment method and declined alternative treatment (active surveillance, radical prostatectomy, and radiation therapy)\n* PSA \u2264 20\n* Ability to complete informed consent form\n\nExclusion Criteria:\n\n* Contraindication to follow-up multi parametric MRI or prostate biopsy\n* Unable to tolerate general or regional anesthesia",
            "healthyVolunteers": true,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Male",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the focal therapy as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Juan Javier-DesLoges, MD",
                    "role": "CONTACT",
                    "phone": "858-657-8786",
                    "email": "jjavierdesloges@health.ucsd.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Diego",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92121",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Juan Javier-DesLoges, MD",
                            "role": "CONTACT",
                            "phone": "858-657-8786",
                            "email": "jjavierdesloges@health.ucsd.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "37553435",
                    "type": "BACKGROUND",
                    "citation": "Javier-DesLoges J, Dall'Era MA, Brisbane W, Chamie K, Washington SL 3rd, Chandrasekar T, Marks LS, Nguyen H, Daneshvar M, Gin G, Kane CJ, Bagrodia A, Cooperberg MR. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. Prostate Cancer Prostatic Dis. 2023 Aug 8. doi: 10.1038/s41391-023-00702-1. Online ahead of print. No abstract available."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}